WuXi Biologics seals top end price for $500m IPO
WuXi Biologics has priced its HK$3.9bn ($500.4m) IPO at the top of guidance after an overwhelming show of demand from institutional and retail investors, according to a banker close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: